We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-5.28%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.16B
AUM Growth
-$686M
Cap. Flow
-$227M
Cap. Flow %
-10.51%
Top 10 Hldgs %
54.85%
Holding
104
New
19
Increased
23
Reduced
7
Closed
33

Sector Composition

Rank Sector Weight
1 Healthcare 32.7%
2 Consumer Discretionary 15.06%
3 Financials 5.94%
4 Communication Services 4.21%
5 Technology 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.33M 0.34%
250,000
LCTX icon
52
Lineage Cell Therapeutics
LCTX
$264M
$6.37M 0.29%
1,588,475
HOG icon
53
CALL
Harley-Davidson
HOG
$2.61B
$6.07M 0.28%
+100,000
New +$6.29M
HOG icon
54
Harley-Davidson
HOG
$2.61B
$6.07M 0.28%
+100,000
New +$6.29M
CCXI
55
DELISTED
ChemoCentryx, Inc.
CCXI
$6.04M 0.28%
800,000
+400,000
+100% +$3.13M
IMGN
56
CALL
DELISTED
Immunogen Inc
IMGN
$5.37M 0.25%
600,000
-400,000
-40% -$2.9M
ACOR
57
CALL
DELISTED
Acorda Therapeutics
ACOR
$4.99M 0.23%
1,250
BRFS
58
DELISTED
BRF SA
BRFS
$4.95M 0.23%
+250,000
New +$5.55M
ONCE
59
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$4.65M 0.22%
+60,000
New +$3.46M
XOMA
60
DELISTED
Xoma
XOMA
$4.37M 0.2%
60,000
RXDX
61
DELISTED
Ignyta, Inc.
RXDX
$4.23M 0.2%
425,000
+25,000
+6% +$187K
ADVM
62
DELISTED
Adverum Biotechnologies
ADVM
$4.05M 0.19%
+10,000
New +$4.23M
IRWD icon
63
Ironwood Pharmaceuticals
IRWD
$586M
$3.47M 0.16%
258,954
CLLS
64
Cellectis
CLLS
$288M
$3.46M 0.16%
+100,000
New +$3.63M
NKTR icon
65
CALL
Nektar Therapeutics
NKTR
$2.39B
$3.3M 0.15%
+20,000
New +$4.11M
ITB icon
66
iShares US Home Construction ETF
ITB
$2.32B
$2.82M 0.13%
+100,000
New +$2.67M
CERE
67
DELISTED
CERES, INC. COMMON STOCK NEW
CERE
$2.7M 0.13%
1,024,021
PARN
68
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$2.46M 0.11%
500,000
AGEN
69
Agenus
AGEN
$276M
$2.1M 0.1%
20,896
LCTX icon
70
CALL
Lineage Cell Therapeutics
LCTX
$264M
$1.99M 0.09%
+495,605
New +$1.71M
CSLT
71
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.94M 0.09%
250,000
AIG icon
72
CALL
American International
AIG
$42.5B
-600,000
Closed -$33.6M
ALLY icon
73
Ally Financial
ALLY
$13.1B
-125,000
Closed -$2.95M
AMRN
74
CALL
Amarin Corp
AMRN
$297M
-25,000
Closed -$490K
ARMK icon
75
Aramark
ARMK
$15B
-415,500
Closed -$9.35M

Similar funds

Artal Group's Q1 2015 Portfolio in Review

As of Q1 2015, Artal Group held 104 positions worth $2.16B, down 24% from $2.85B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Artal Group withdrew a net $227M in Q1 2015, closing 33 positions and reducing 7 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $27.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Bank of America worth $18.5M.

  • Artal Group's largest Q1 2015 buy was Bank of America: 1,200,000 shares worth $18.5M.
  • Artal Group added most to Alphabet (Google) Class C in Q1 2015, an estimated $34.9M increase.
  • Artal Group's biggest Q1 2015 reduction was Aptiv, cutting an estimated $1.88M.
  • Artal Group fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $27.5M.
  • Artal Group's ten largest holdings make up 55% of its $2.16B portfolio in Q1 2015.
  • Artal Group opened 19 new positions and closed 33 in Q1 2015.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $2.16B.

Based on Artal Group's 13F filing for Q1 2015, filed 13 May 2015.